Amarantus Reports Second Quarter 2014 Financial Results, Announces Business Update Call

SAN FRANCISCO and GENEVA, Aug. 27, 2014 (GLOBE NEWSWIRE) — Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic intervent…Read More »

Amarantus to Present at Upcoming Investor Conferences

SAN FRANCISCO, Aug. 19, 2014 (GLOBE NEWSWIRE) — Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutic…Read More »

Amarantus Exercises Option to License Intellectual Property From University of Miami Bascom Palmer Eye Institute for Use of MANF in Retinal Disorders

SAN FRANCISCO, GENEVA and MIAMI, Aug. 15, 2014 (GLOBE NEWSWIRE) — Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnosti…Read More »

Amarantus Enters Into Research Collaboration With the Buck Institute for Research on Aging for MANF

Company Acquires Exclusive Option to License Undisclosed MANF IP SAN FRANCISCO and GENEVA and NOVATO, Calif., Aug. 11, 2014 (GLOBE NEWSWIRE) — Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biot…Read More »

#C4CT Summit Explored Emerging Theories on Traumatic Brain Injury, Chronic Traumatic Encephalopathy and Possible Links to Alzheimer's Disease

Raises Concerns for Early, Sub-Concussive Hits and Calls for Collaboration SAN FRANCISCO, GENEVA and MINNEAPOLIS, Aug. 4, 2014 (GLOBE NEWSWIRE) — Brewer Sports International (BSI), a multi-faceted gl…Read More »
Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS) is a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis (programmed cell death).

Company Information

Company Website: http://www.amarantus.com/
Company Headquarters

c/o Janssen Labs @ QB3
953 Indiana Street
San Francisco, CA 94107
Phone: (408) 737-2734
Fax: (408) 852-4427
info@amarantus.com

Media and Investor Relations Contact

Aimee Boutcher, Director of Investor Relations
Phone: (408) 737-2734 x 101
ir@amarantus.com

Forward Looking Statements

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements." These forward-looking statements generally are identified by the words believes," project," expects," anticipates," estimates," intends," strategy," plan," may," will," would," will be," will continue," will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

This Blog is official and sanctioned by Amarantus BioScience | See Disclaimer | See Privacy Policy

Get Amarantus BioScience Blog Post Alerts